Lior Shaltiel

[Progress, Potential, And Possibilities @ProgressPotent1]

What if paralysis 👨‍🦽 wasn’t permanent - or at least not untreatable?

What if we could deliver regenerative signals to the central nervous system… through a simple intranasal spray?

In our latest @ProgressPotent1, @liorshal (CEO of @NBiologic) breaks down the science behind ExoPTEN - an exosome-based therapy designed to deliver siRNA and temporarily silence the PTEN signaling pathway, one of the nervous system’s key “brakes” on regeneration. 🚀

In preclinical models, this approach has shown something rarely seen in this field: meaningful functional recovery after severe spinal cord injury.

We explore:
- Why the central nervous system struggles to regenerate;
- Whether exosomes can finally solve the delivery problem;
- Dr. Shaltiel’s journey-from ion channel biophysics to leading one of the more ambitious bets in neuroregeneration;

Watch here: https://t.co/CAf2T5b0YI

#Biotech #Neuroscience #SpinalCordInjury #RegenerativeMedicine #Exosomes #Neuroregeneration #GeneSilencing #FutureOfMedicine #HealthTech #Longevity @russopartners @HebrewU

[NurExone Biologic (TSXV: NRX) (Germany: J90) @NBiologic]

A really important milestone for NurExone....

Read more: https://t.co/knXfjssOl7

[NurExone Biologic (TSXV: NRX) (Germany: J90) @NBiologic]

⚡ NurExone’s exosomes show significant anti-inflammatory activity, outperforming commercial alternatives in new laboratory analysis!

#Biotech #Exosomes #RegenerativeMedicine #Innovation #NurExone $NRX

Read here: https://t.co/yntSHBIXlO

[NurExone Biologic (TSXV: NRX) (Germany: J90) @NBiologic]

Read more about NurExone's Regenerative Therapy for CNS injuries under development: https://t.co/G96sUsilYv

[NurExone Biologic (TSXV: NRX) (Germany: J90) @NBiologic]

Shana Tova!

[NurExone Biologic (TSXV: NRX) (Germany: J90) @NBiologic]

🔬✨ In biotech, IP is a great moat!!

Proud that we received a U.S. Patent Allowance for our proprietary process of producing exosomes!

https://t.co/OeqpkPUKpl

[NurExone Biologic (TSXV: NRX) (Germany: J90) @NBiologic]

The potential of regenerative medicine to help with conditions we don't have answers to!

Learn more!: https://t.co/istyeOISzn

[NurExone Biologic (TSXV: NRX) (Germany: J90) @NBiologic]

The Science Behind the Magic ✨

Drug Discovery World took a deep look at the mechanisms behind our exosome therapy, designed to help damaged nerves regenerate, rewire and recover, and what it takes to translate to clinical .

Read more: https://t.co/R6O6eXJRPy

[NurExone Biologic (TSXV: NRX) (Germany: J90) @NBiologic]

Check out our October 90-Second Month in Review!

[NurExone Biologic (TSXV: NRX) (Germany: J90) @NBiologic]

https://t.co/cen2pdcBA3

Large scale preclinical testing to be performed on ExoPTEN.. A step closer to clinical trials and added hope for patients with acute spinal cord injuries....

#ExoTherapy #Nanodrugs #OrphanDrugs #Medicalinnovation

[NurExone Biologic (TSXV: NRX) (Germany: J90) @NBiologic]

https://t.co/9Ck25nQwfe

Read all about ExoPTEN - an innovative therapy under development by NurExone for patients with acute spinal cord injuries!

#Unlockinghope #MedicalInnovation

[NurExone Biologic (TSXV: NRX) (Germany: J90) @NBiologic]

Professor Shulamit Levenberg, of the Technion - Israel Institute of Technology, reflects on the beginning of NurExone and its exosome-based therapy for spinal cord regeneration.

https://t.co/gl7DYVSqpM

[Eylon Levy @EylonALevy]

The first question that left me speechless (but only for a second):

[NurExone Biologic (TSXV: NRX) (Germany: J90) @NBiologic]

Compliments to our CEO Dr. Lior Shaltiel, PhD as per his recent nomination as co-chair of the Israeli organization for engineering, architecture and technological industries - the Med-Tech.

https://t.co/LewUdd2SoH

#biotechnology #israelitech #engineering #biotechorganization

[Lior Shaltiel @liorshal]

I mark personally a significant milestone as NurExone Biologic celebrates its one-year anniversary as a public traded company! 🚀 🎉

I extend our heartfelt thanks to our incredible team, supportive shareholders, and valued stakeholders for their crucial…https://t.co/AM9SARBDv1

[Lior Shaltiel @liorshal]

Cheers for the wonderful first year as a public company and many year to come!

[NurExone Biologic (TSXV: NRX) (Germany: J90) @NBiologic]

@NBiologic is publicly traded for 1 year 👏
We are pleased to share here some of our scientific and business' achievements.

Looking forward to the success ahead of us! 🥂

[NurExone Biologic (TSXV: NRX) (Germany: J90) @NBiologic]

From all of us at NurExone Biologic, we wish you a happy Passover 🌸

#passover2023 #springtime #nationalholiday

[NurExone Biologic (TSXV: NRX) (Germany: J90) @NBiologic]

NurExone Biologic reports additional positive preclinical trial outcomes with ExoPTEN: 75% of paralyzed rats show recovery after Acute Spinal Cord Injury study!
Read the full PR here:
https://t.co/bRdcBa57OR

[Lior Shaltiel @liorshal]

This Wednesday (Feb 15th), I will attend the OurCrowd summit in Jerusalem.
Happy to meet and discuss with individuals and potential Investors who are interesting in NurExone Biologic's unique therapy and technology platform to trea…https://t.co/1c4JgFLwTS https://t.co/8SSobdl68O

[Lior Shaltiel @liorshal]

Introduction to our International MBA programs at The Hebrew University Business School
Date: Sunday, January 29, 2023
Time: 6:00PM JLM

Register here: https://t.co/rXyx6lpTfB https://t.co/Zl4YIZ2sTI